Heterocyclic replacements for the carboxamido group of the previously
disclosed phenylglycinol-based human NK1 (hNK(1)) receptor antagonists
have been investigated, ultimately leading to acyclic compounds with
sub-nanomolar affinity for the hNK(1) receptor. (C) 1997 Elsevier Scie
nce Ltd. All rights reserved.